Ferring Pharma acquires two Ph III-ready orthobiologics from BioSET

19 February 2015

Privately-held Switzerland-headquartered Ferring Pharmaceuticals has acquired the assets of USA-based BioSurface Engineering Technologies (BioSET), including two Phase III-ready orthobiologic product candidates designed to improve bone repair.

The initial indications for Amplex and Prefix to be investigated are fusion in foot/ankle and lumbar spine surgical procedures, respectively. Both products are based on a unique biomimetic peptide designed to enhance the body’s own natural mechanisms of bone repair.

Orthopedics has grown to become one of five key therapeutic areas for Ferring since the 2005 launch of Euflexxa (1% sodium hyaluronate) for the treatment for knee pain due to osteoarthritis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK